Clinical Trials
155
22 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1867
Active, not recruiting
6
3.9%
Completed
83
53.5%
Enrolling By Invitation
4
2.6%
Not yet recruiting
12
7.7%
Recruiting
19
12.3%
Terminated
13
8.4%
Unknown
2
1.3%
Withdrawn
16
10.3%
No approval data available
- Continuity Biosciences has launched a Phase I clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for pancreatic cancer treatment. - The proprietary IOP platform aims to enable localized, controlled delivery of therapeutics directly into pancreatic tumors while minimizing systemic toxicity. - The study is now enrolling patients at leading academic medical centers including West Virginia University and University of Michigan. - Pancreatic cancer remains one of the leading causes of cancer-related mortality with five-year survival rates in the low double digits.
- Medtronic received FDA approval for its next-generation Mosaic Neo mitral bioprosthesis, designed for implantation through sternotomy, minimally invasive cardiac surgery, and robotic access. - The valve features enhanced design improvements including reduced left ventricular stent post protrusion, wide anterior distance between stent posts, and improved visualization under fluoroscopy. - Initial implants have been successfully performed at major U.S. hospitals, with the first robotic implantation and first concomitant use with Medtronic's Penditure LAA Exclusion System already completed. - Nearly 20,000 patients undergo surgical mitral valve replacement annually in the U.S., representing a significant market opportunity for this enhanced valve technology.
- Bassett Research Institute has been awarded approximately $12 million from PCORI to conduct a multi-center clinical trial examining kidney effects of vancomycin and piperacillin/tazobactam combination therapy in hospitalized patients with severe infections. - The study aims to resolve clinical uncertainty about whether VPT causes more acute kidney injury compared to alternative antibiotic regimens, using advanced kidney function testing with serum cystatin C as the primary outcome. - Approximately 1,000 hospitalized adult patients will be enrolled across over two dozen sites nationwide, with the research designed to provide evidence-based guidance for antibiotic selection in severe infections. - The trial addresses a critical evidence gap that currently leads to practice variation among clinicians when choosing between VPT and non-VPT antibiotic regimens for treating serious infections.
- Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide. - The company announced new partnerships with academic medical centers including Emory University, West Virginia University, and West Clinic, joining previously established collaborations with USC Keck School of Medicine and Medical College of Wisconsin. - Ryght AI's platform addresses critical industry inefficiencies where sponsors spend up to $50,000 activating a single site and $50,000-$500,000 enrolling each patient, with 55% of trials failing due to poor site feasibility. - The AI-driven solution reduces traditional feasibility timelines from several months to less than three weeks through automated workflows and real-time site performance data.
- ZEISS INTRABEAM 700 has received FDA 510(k) clearance, offering robotic-assisted precision for intraoperative radiation therapy in neuro-oncology and breast cancer treatment. - The platform features a digital-first architecture with SMART Workflow Efficiency, including sterile single-use applicators, intuitive controls, and Radiance™ treatment planning software for pre-operative simulation. - Currently being evaluated in multiple clinical trials including INTRAGO-II for glioblastoma and TARPIT-E for breast cancer, with results expected between 2025-2027.
- West Virginia University (WVU) will conduct a study comparing oral film versus injectable buprenorphine for opioid use disorder treatment in rural areas. - The study, funded by the National Institute on Drug Abuse, will involve 24 patients at a clinic in New Martinsville, Wetzel County, and six other sites nationwide. - Senate Bill 2028 allows researchers to dispense larger amounts of buprenorphine directly to study participants, bypassing pharmacy distribution. - The research will assess drug abstinence, life improvements, and mental health symptom changes in patients receiving different buprenorphine formulations.
- The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care. - Three inaugural research hubs have been selected at Oregon Health and Science University (OHSU), University of Wisconsin-Madison (UW), and West Virginia University (WVU). - The network will focus on improving access to clinical research for underserved communities and those underrepresented in research. - Initial studies will address chronic back pain, polysubstance abuse, and gout, engaging rural communities through existing NIH-funded trials.
